MVM leads investment round in SkyCell

In April 2020, MVM led the growth investment round in SkyCell, a company that has developed patented temperature-control technology to safely transport vaccines and biotechnology drugs by air. SkyCell technology avoids the need for active refrigeration, lowers the costs of transport and reduces potential damage to vital pharmaceutical products.

MVM’s Hugo Harrod and Jack Tanaka will join the SkyCell board.

SkyCell AG

SkyCell AG
Cold chain technology

MVM Portfolio
View SkyCell AG in portfolio

Website
www.skycell.ch

Latest News

Valneva announces major COVID-19 vaccine partnership with UK government

UK government invests in Valneva's manufacturing facility and secures supply of 60 million doses of Valneva's inactivated COVID-19 vaccine VLA2001, with option for another 130 million doses.

MVM Summer 2020 Newsletter

Recent updates regarding MVM team, new investments, and portfolio.

MVM invests in Paragon 28

MVM co-led the Series B financing of Paragon 28, a leading orthopedic foot and ankle company.

Valneva confirms participation in UK government COVID-19 vaccine response program

Valneva has reached agreement in principle with the UK government to provide up to 100 million doses of its SARS-CoV-2 vaccine candidate.

MVM invests in MDxHealth SA

MVM closed a growth investment in MDxHealth SA, a company that markets tests that optimize the care of patients with prostate cancer.

MVM leads investment round in SkyCell

MVM led the growth investment round in SkyCell, a company that has developed patented temperature-control technology to transport vaccines and biotechnology drugs.